RIC once per day for Vascular Cognitive Impairment

Foothills Medical Centre, Calgary, Canada
Vascular Cognitive Impairment+3 More ConditionsRemote ischemic conditioning - Device
60 - 85
All Sexes
What conditions do you have?

Study Summary

This trial will test whether RIC is a tolerable and effective treatment for patients with cognitive impairment due to cerebral small vessel disease.

Eligible Conditions
  • Vascular Cognitive Impairment
  • Cerebral Small Vessel Disease
  • Vascular Dementia

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

1 Primary · 11 Secondary · Reporting Duration: 30 days and 90 days

14 days
30 days
Arm deep venous thrombosis
Physical examination
Day 90
Global cognition
MRI cerebral blood flow
MRI diffusion tensor imaging
Magnetic Resonance Imaging
Neuropsychiatric symptoms
Neuropsychological tests

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

RIC once per day
1 of 2
RIC twice per day
1 of 2

Active Control

24 Total Participants · 2 Treatment Groups

Primary Treatment: RIC once per day · No Placebo Group · Phase 2

RIC once per day
ActiveComparator Group · 1 Intervention: Remote ischemic conditioning · Intervention Types: Device
RIC twice per day
ActiveComparator Group · 1 Intervention: Remote ischemic conditioning · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days and 90 days

Who is running the clinical trial?

University of CalgaryLead Sponsor
728 Previous Clinical Trials
573,634 Total Patients Enrolled
Canadian Consortium on Neurodegeneration in AgingOTHER
3 Previous Clinical Trials
3,050 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,267 Previous Clinical Trials
25,601,485 Total Patients Enrolled
Eric Smith, MDPrincipal InvestigatorUniversity of Calgary

Eligibility Criteria

Age 60 - 85 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Does this trial currently have any available openings for participants?

"Per the information on clinicaltrials.gov, this research trial is actively seeking participants. The study was made public on September 26th 2019 and its details were recently updated June 7th 2022." - Anonymous Online Contributor

Unverified Answer

What is the current size of the cohort engaging in this research?

"Affirmative - the online data hosted on clinicaltrials.gov demonstrates that this medical trial is currently enrolling, with its first posting being dated September 26th 2019 and last updated June 7th 2022. Qualified candidates are sought from 1 centre for a total of 24 patients." - Anonymous Online Contributor

Unverified Answer

Is participation in this trial available for individuals?

"This medical trial is seeking 24 seniors between the ages of 60 and 85 with cerebral small vessel diseases. In order to qualify, participants must demonstrate independence in completing basic activities of daily living (responding positively to questions 2, 4, 5, 6, 7 8 9 and 14 on Bristol ADL scale), have visible evidence of CSVD on MRI or CT scans such as confluent white matter hypodensities/hyperintensities (ARWMC Scale) or two+ supratentorial infarcts; score <25 on Montreal Cognitive Assessment Test; exhibiting a noticeable decline from their previous cognitive functioning level according to patients" - Anonymous Online Contributor

Unverified Answer

Is the sample population of this research encompassing individuals aged sixty and above?

"The requirements for participation in this clinical trial mandate that applicants must fall within the age range of 60 to 85 years old. 57 trials are available for minors, and 937 studies offer enrollment opportunities to seniors." - Anonymous Online Contributor

Unverified Answer

Has the FDA sanctioned twice-daily administration of RIC?

"Our team has awarded RIC twice per day a rating of 2 due to the Phase 2 trial status, meaning there is sufficient evidence for safety but insufficient data on efficacy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.